{"cluster": 62, "subcluster": 23, "abstract_summ": "The present study evaluated the possibility of plant originated approved 117 therapeutics against the main protease protein (MPP), RNA-dependent RNA polymerase (RdRp) and spike protein (S) of SARS-CoV-2 including drug surface analysis by using molecular docking through drug repurposing approaches.Here, we applied a molecular docking method to study the binding stability of these drugs with SARS-CoV-2 Mpro.The selected drug target proteins were screened against an in-house library of 123 antiviral drugs.From the virtual screening results, two drug molecules were selected for each drug target protein [Paritaprevir (\u0394G = \u22129.8 kcal/mol) & Raltegravir (\u0394G = \u22127.8 kcal/mol) for 3CLpro and Dolutegravir (\u0394G = \u22129.4 kcal/mol) and Bictegravir (\u0394G = \u22128.4 kcal/mol) for 2\u2032-OMTase].Research efforts to develop antiviral agents against coronavirus demonstrated the main protease (Mpro) protein may represent effective drug target.", "title_summ": "Structure-Based Design, Synthesis and Biological Evaluation of Peptidomimetic Aldehydes as a Novel Series of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main ProteaseVirtual Screening of Plant Metabolites against Main protease, RNA-dependent RNA polymerase and Spike protein of SARS-CoV-2: Therapeutics option of COVID-19Discovery of New Hydroxyethylamine Analogs against 3CL(pro) Protein Target of SARS-CoV-2: Molecular Docking, Molecular Dynamics Simulation, and Structure\u2013Activity Relationship StudiesA molecular modeling approach to identify effective antiviral phytochemicals against the main protease of SARS-CoV-2Identification of potential natural inhibitors of SARS-CoV2 main protease by molecular docking and simulation studiesStructural basis of SARS-CoV-2 3CL(pro) and anti-COVID-19 drug discovery from medicinal plantsPrediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidatesDiscovery of alliin as a putative inhibitor of the main protease of SARS-CoV-2 by molecular dockingUnravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M(pro) enzyme through in silico approachSars-cov-2 host entry and replication inhibitors from Indian ginseng: an in-silico approachRecognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico EvidencesVirtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2)Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2\u2032-O-ribose methyltransferaseStructure-based design of antiviral drug candidates targeting the SARS-CoV-2 main proteaseActivity profiling and structures of inhibitor-bound SARS-CoV-2-PLpro protease provides a framework for anti-COVID-19 drug designPossible SARS-coronavirus 2 inhibitor revealed by simulated molecular docking to viral main protease and host toll-like receptorDesign, synthesis and molecular docking of novel triazole derivatives as potential CoV helicase inhibitors.Potential of NO donor furoxan as SARS-CoV-2 main protease (Mpro) inhibitors: in silico analysis.", "title_abstract_phrases": "The present study evaluated the possibility of plant originated approved 117 therapeutics against the main protease protein (MPP), RNA-dependent RNA polymerase (RdRp) and spike protein (S) of SARS-CoV-2 including drug surface analysis by using molecular docking through drug repurposing approaches.Possible SARS-coronavirus 2 inhibitor revealed by simulated molecular docking to viral main protease and host toll-like receptorAim: SARS-coronavirus 2 main protease (Mpro) and host toll-like receptors (TLRs) were targeted to screen potential inhibitors among traditional antiviral medicinal plants.In view to expedite new drug leads for COVID-19, Main Proteases (Mpro) of novel Coronavirus (SARS-CoV-2) has emerged as a crucial target for this virus.The selected drug target proteins were screened against an in-house library of 123 antiviral drugs.From the virtual screening results, two drug molecules were selected for each drug target protein [Paritaprevir (\u0394G = \u22129.8 kcal/mol) & Raltegravir (\u0394G = \u22127.8 kcal/mol) for 3CLpro and Dolutegravir (\u0394G = \u22129.4 kcal/mol) and Bictegravir (\u0394G = \u22128.4 kcal/mol) for 2\u2032-OMTase]."}